We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.

Delisted

NAVB was delisted on the 5th of October, 2023.

78 hedge funds and large institutions have $60.2M invested in Navidea Biopharmaceuticals Inc. in 2015 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

4% less funds holding

Funds holding: 8178 (-3)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

52% less capital invested

Capital invested by funds: $126M → $60.2M (-$66M)

97% less call options, than puts

Call options by funds: $213K | Put options by funds: $8.2M

Holders
78
Holders Change
-3
Holders Change %
-3.7%
% of All Funds
2.05%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
28
Reduced
18
Closed
11
Calls
$213K
Puts
$8.2M
Net Calls
-$7.99M
Net Calls Change
+$5.71M

NAVB Hedge Fund Activity: Q4 2015 in Review

78 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2015, worth a combined $60.2M — down 52% from $126M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of NAVB and 8 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 28 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $333K. The largest seller was Platinum Management, cutting an estimated $16.1M.

  • 78 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2015, down from 81 in Q3 2015.
  • Funds reported $60.2M of Navidea Biopharmaceuticals Inc. stock for Q4 2015, down 52% quarter-over-quarter.
  • 8 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2015 and 11 closed out, a net change of -3 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2015 was BlackRock Institutional Trust, an estimated $333K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q4 2015 was Platinum Management, an estimated $16.1M sold.

Based on aggregated 13F filings for Q4 2015.